Replies to post #117697 on Biotech Values

[Whosetosay]

Certainly some of the subset data will better than what we have seen so far, so there is little chance of this being a washout.

If some unfavorable Rida data is found, and Merck confirms the combo strength of Rida in its other trials, and of course, who wouldn't want Pona, I could see Mrk trying a bid on any serious weakness in ARIA.

[BTH]

I think, currently, Merck's oncology division is incredibly weak.